China Medical Device Registration vs. EU MDR: 5 Key Differences
For manufacturers already certified under the European Medical Device Regulation (Regulation (EU) 2017/745), it is tempting to assume that China medical device registration is mainly a matter of translation. A look at the official rules on both sides shows otherwise: the two systems differ structurally in several key areas. The overview below and the five differences that follow help regulatory and project teams set realistic timelines and budgets.
Key takeaways
- In China, a state body (CMDE or a provincial authority) reviews the dossier — there is no free choice of a Notified Body like in Europe.
- Overseas manufacturers must appoint a domestic agent in China, comparable to but broader than the EU Authorized Representative.
- Mandatory Chinese standards apply; a CE mark does not replace China's own technical review.
- Both systems cap certificates at five years, but China fixes statutory review periods (60/90 working days) and a six-month renewal deadline.
- ISO 13485 is a strong foundation, and China's revised medical device GMP applies from 1 November 2026.
EU MDR vs. China at a Glance
| Aspect | EU (MDR) | China (NMPA / CMDE) |
|---|---|---|
| Who reviews the dossier | Private, EU-notified Notified Body chosen by the manufacturer | State-run CMDE (domestic Class III / all imported) or provincial authority (domestic Class II) |
| Local representative | Authorized Representative (Art. 11 MDR) | Domestic agent, mandatory for overseas applicants (Art. 14) |
| Standards | Harmonised EU standards (presumption of conformity) | Mandatory Chinese standards (GB/YY); self-test report allowed (Art. 19, 32) |
| Clinical evaluation | Equivalence via existing clinical data (Art. 61 MDR) | Exemption list or analysis of existing data; local clinical trial if insufficient (Art. 33–36) |
| Validity & timelines | Certificate max. 5 years (Art. 56(4) MDR); review time depends on Notified Body | 5 years (Art. 58); renewal 6 months before expiry (Art. 82); review 60/90 working days (Art. 92) |
| QMS requirements | MDR Art. 10(9); ISO 13485 as harmonised standard | China medical device GMP; revised version in force from 1 Nov 2026 |
1. Who Reviews the Dossier: Private Notified Body vs. State Authority
Under the MDR, manufacturers engage an independent, EU-notified “Notified Body” to carry out the conformity assessment of higher-risk devices. This model does not exist in China. According to the official Provisions for Medical Device Registration and Filing (SAMR Decree No. 47), the technical review of registration applications for domestic Class III devices and all imported devices sits with the state-run Center for Medical Device Evaluation (CMDE); for domestic Class II devices, the provincial drug regulatory departments carry out the review. Manufacturers therefore cannot choose their reviewer, as EU manufacturers can with Notified Bodies.
2. Local Representation: Authorized Representative vs. Domestic Agent
Both systems require manufacturers based outside the market to appoint a local representative. Article 14 of the Chinese Provisions requires overseas applicants to designate a domestic legal entity as their agent, who supports the fulfilment of the registrant's obligations and shares legal responsibility. The role is comparable to the Authorized Representative under Article 11 MDR, but broader in practice, since the Chinese agent stays involved in reporting, change and renewal procedures throughout the product lifecycle.
3. Standards: Mandatory Chinese Standards Instead of Harmonised EU Standards
Under Article 19 of the Provisions, medical devices must comply with applicable mandatory Chinese standards; if a device deviates from a mandatory standard in structure or intended use, the applicant must justify this. In the EU, by contrast, applying harmonised European standards creates a presumption of conformity. One point in manufacturers' favour: under Article 32, the test report may be either a self-test report by the applicant or a report from a commissioned, qualified testing institution — a flexibility in place since the 2021 reform.
4. Clinical Evaluation: Exemption List and Chinese Criteria
Articles 33 to 36 of the Provisions require a clinical evaluation unless the device appears on the exemption list published by the NMPA or its safety can be demonstrated through non-clinical evaluation. Where an evaluation is required, it can be based on an analysis of existing clinical literature and data on comparable devices; if that data is insufficient, a clinical trial in China is required. Conceptually, this resembles the equivalence approach under Article 61 MDR, but it follows China's own criteria — European clinical evaluations are not automatically recognised.
5. Validity and Statutory Timelines
A Chinese registration certificate is valid for five years (Article 58), and the renewal application must be submitted six months before expiry (Article 82). Review periods are also fixed by law: 60 working days of technical review for Class II devices and 90 working days for Class III devices (Article 92), plus any time needed for supplementary information. For comparison, Notified Body certificates under the MDR are also limited to a maximum of five years (Article 56(4) MDR). The difference therefore lies not in validity itself, but in China's statutory review periods and fixed renewal deadline, whereas in the EU the review duration depends more on the individual Notified Body's capacity.
What's Changing: China's Revised Medical Device GMP from 1 November 2026
China's quality management requirements for manufacturers are set out in its Good Manufacturing Practice (GMP) for medical devices. The NMPA released a revised version through Announcement No. 107 of 2025, which comes into force on 1 November 2026 and replaces the 2014 version. According to the NMPA, the revised GMP comprises 15 chapters and 132 articles and adds three new chapters on quality assurance, verification and validation, and contract manufacturing and outsourcing. For manufacturers already working to ISO 13485, many of these themes will be familiar, but the Chinese requirements should be reviewed in their own right.
Why This Matters for Your Company
An established ISO 13485-certified quality management system and MDR certification for the EU market are an excellent starting point for China medical device registration — but they do not replace the CMDE's independent technical review or compliance with China's medical device GMP. Teams that understand where the two systems diverge structurally avoid unrealistic timelines and late surprises in their projects.
Going from EU MDR to China?
Your MDR experience gives you a strong foundation—but China has its own regulatory rules, review process and quality requirements. Learn how medical device registration works in practice and what to consider when planning your registration project.
About this article
This article was reviewed and validated by Jane Li, Director of Medical Devices China and Technical File Reviewer at DQS.
Frequently Asked Questions: EU MDR vs. China Medical Device Registration
What is the biggest difference between EU MDR and China medical device registration?
In the EU, a privately chosen, EU-notified Notified Body carries out conformity assessment. In China, technical review sits with the state-run CMDE — or, for domestic Class II devices, with the provincial authority — and manufacturers cannot choose their reviewer.
Do I need a local representative in China, like the EU Authorized Representative?
Yes. Article 14 of China's Provisions for Medical Device Registration and Filing requires overseas applicants to appoint a domestic agent, who supports the registrant's obligations and shares legal responsibility — a broader, ongoing role than the EU Authorized Representative.
Is a CE mark recognised for medical device registration in China?
Not automatically. Proof of marketing approval in the country of origin is part of the dossier for imported devices, but devices must meet mandatory Chinese standards and still undergo China's own technical review by the CMDE.
Are certificates valid for different periods in the EU and China?
Not fundamentally. MDR certificates issued by Notified Bodies are valid for up to five years (Art. 56(4) MDR), as are Chinese registration certificates (Art. 58). The difference is that China sets statutory review periods of 60 or 90 working days (Art. 92) and a fixed renewal deadline six months before expiry (Art. 82).
Does China accept EU clinical evaluation reports?
Not automatically. China allows the use of existing clinical data or an exemption list, but applies its own criteria (Art. 33–3536). If existing data is insufficient, a clinical trial in China may be required.
Does ISO 13485 or MDSAP certification help with China medical device registration?
ISO 13485 provides a solid foundation for the quality management documentation China requires, but it does not replace China's medical device GMP or the CMDE technical review. MDSAP does not cover China, as China is not part of the program.